HOME > BUSINESS
BUSINESS
- FDA Rejects Seikagaku’s Herniated Disk Drug
March 14, 2025
- Glaucoma Eye Drop Rocklatan Now Available in Singapore: Santen
March 14, 2025
- Pfizer Japan Files NDA for Tucatinib for HER2 Breast Cancer
March 14, 2025
- Mitsubishi Tanabe’s Oral Edaravone Filed in South Korea
March 14, 2025
- Biogen Japan to Launch ALS Drug Qalsody upon Listing on March 19
March 14, 2025
- Rxulti Expands Label into Schizophrenia in Adolescents in Europe
March 14, 2025
- Ono Licenses in Polycythemia Vera Drug Candidate from Ionis
March 13, 2025
- More than Half of Drug Makers’ Top 5 Meds See Flat or Positive Revisions: Poll
March 12, 2025
- Two-Thirds of Drug Makers Discontent with FY2025 Price Revision: Survey
March 11, 2025
- Chugai CEO Vows to Cherish Employees at 100th Anniversary
March 11, 2025
- Kyowa Kirin/Amgen’s Eczema Drug Hits Main Goal in Global PIII
March 11, 2025
- Drug Makers Weigh Withdrawal of Unprofitable Drugs, Generic and Innovative Players Alike: Poll
March 11, 2025
- Daiichi Curbs Enhertu Shipments on Spiking Demand in Japan
March 11, 2025
- Amitiza Notches Triple Crowns in Hospital Doctor Promotion in January: Intage
March 11, 2025
- Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll
March 10, 2025
- Astellas, Yaskawa Electric to Form JV for Cell Therapy Production
March 10, 2025
- Sandoz’s Rituxan Biosimilar Adds Nephrotic Syndrome Use
March 10, 2025
- Japan Ethical Drug Sales Up 3.8% in January: Crecon
March 10, 2025
- Novartis Adjusts Entresto Shipments Ahead of Price Hike in Off-Year Revision
March 7, 2025
- Off-Year Revision Is Problematic, Leads to Hesitation in Investment: Novo CEO
March 7, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
